All In Biotech

Drug Trial Radar · NCT06149520

A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of BAY 3018250 in Patients With Symptomatic Proximal Deep Vein Thrombosis

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 283 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

283

Actual

Start

Jan 15, 2024

Primary completion

Oct 7, 2025

Study completion Dec 2, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people who have deep vein thrombosis (DVT). DVT is a condition that occurs when a blood clot forms in a deep vein in the leg. DVT is called 'proximal' when the clot is formed in the veins of the hip, thigh, and knee. DVT can cause serious health problems. The blood clots in the veins can break loose and can then travel through the bloodstream and get stuck in the lungs, blocking blood flow to the lungs. Symptoms of DVT include swelling, pain, and tenderness in the affected leg, as well as redness and warmth in the area. Currently, DVT is usually treated using blood thinners to prevent the clot from getting bigger or breaking off and traveling to the lungs. However, blood thinners may not be able to remove a blood clot quickly and may not be suitable for everyone who has DVT. BAY3018250 is a drug that works by dissolving blood clots. In this study, researchers will compare BAY3018250 with placebo to learn how well it works and how safe it is in participants with proximal DVT. A placebo looks like the study drug but does not have any medicine in it. Using a placebo helps researchers to confirm that the results observed during the study were caused by the study drug and not by other factors. The main purposes of this study are to learn: * How well BAY3018250 works in dissolving blood clots in participants with proximal DVT and * How safe is BAY3018250 as a treatment for participants with proximal DVT? For this, the researchers will use ultrasound tests to measure blood clots in participants before and at various times after study treatment. They call these measurements a clot burden score. They will compare the clot burden score before and after treatment and will calculate a complex measure called AUC. This tells researchers how the clots have changed over time. And researchers will collect the number of bleeding events that require medical attention. The study participants will be randomly (by chance) assigned to one of 3 treatment groups. Dependent on the group, they will receive a single dose of high dose or low dose of BAY3018250 or placebo. Researchers will closely monitor participants for 90 days after receiving the study treatment. During the study, the doctors and their study team will: * take blood samples * do physical examinations * examine heart health using electrocardiogram (ECG) * check vital signs such as blood pressure, heart rate * undergo ultrasound tests to measure the blood clots * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

Conditions

  • Thrombolysis
  • Symptomatic Proximal Deep Vein Thrombosis

Interventions

  • BAY3018250Drug

    Dose 1 or dose 2 of BAY3018250

  • Placebo to BAY3018250Drug

    Matching placebo to BAY3018250

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCn(6h-30d) of the ratio to baseline of clot burden, as assessed by repeated quantitative ultrasoundTime frame: at 6 hours, 24 hours, Day 7, Day 30
  2. Number of participants with composite of major and clinically relevant non-major (CRNM) bleeding events (ISTH definition)Time frame: up to Day 15

Locations

68 sites in 13 countries. Site status is shown where the registry gives one.

  • Universiteit Ziekenhuis Antwerpen | Thoraxheelkunde Afdeling

    Antwerp, Belgium

  • Imelda - Vascular Surgery Dept

    Bonheiden, Belgium

  • Ziekenhuis Oost-Limburg | Genk, Sint-Jan campus - Thoracic Vascular Surgery Department

    Genk, Belgium

  • UZ Gent

    Ghent, Belgium

  • AZ Groeninge - Campus Kennedylaan

    Kortrijk, Belgium

  • Katholieke Universiteit Leuven (KU Leuven) - Center for Molecular and Vascular Biology (CMVB)

    Leuven, Belgium

  • AZ Sint-Maarten

    Mechelen, Belgium

  • University Multiprofile Hospital For Active Treatment Kanev AD

    Rousse, Bulgaria

  • Specialized Hospital For Active Cardiology Treatment Medica Kor EAD

    Rousse, Bulgaria

  • University Multiprofile Hospital For Active Treatment 'Alexandrovska' EAD

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment 'Sveta Ekaterina' EAD, Sofia

    Sofia, Bulgaria

  • Medical Institute Ministry of Interior

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment Dr. Stefan Cherkezov | Base 1 - Cardiology Department

    Veliko Tarnovo, Bulgaria

  • McGill University Health Centre - Glen Site

    Montreal, Quebec, Canada

  • Vojenská nemocnice Brno - Interní oddelení, pododbor kardiologie

    Brno, Czechia

  • Interni oddeleni, Krnovska nemocnice, Sdruzene zdravotnicke zarizeni Krnov, prispevkova organizace

    Krnov, Czechia

  • Kardiologicka klinika, Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia

  • Všeobecná fakultní nemocnice v Praze - II. interní klinika - klinika kardiologie a angiologie, AJIP

    Prague, Czechia

  • Nemocnice Roudnice nad Labem - interni oddeleni

    Roudnice nad Labem, Czechia

  • Interni a kardiologicka ambulance, Nemocnice Znojmo, prispevkova organizace

    Znojmo, Czechia

  • Centre Hospitalier Universitaire Amiens Picardie Site Sud

    Amiens Cedex1, France

  • Centre Hospitalier Regional Universitaire (CHRU) Brest - Hopital de la Cavale Blanche

    Brest, France

  • Centre Hospitalier Universitaire de Clermont Ferrand - Gabriel Montpied

    Clermont-Ferrand, France

  • Hôpital Louis Mourier - Colombes Cedex

    Colombes, France

  • Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes) - Hopital Albert Michallon

    La Tronche, France

  • AP-HP Hopital Europeen Georges-Pompidou (HEGP) - Service de medecine vasculaire

    Paris, France

  • Centre Hospitalier Universitaire (CHU) de Saint-Etienne - Hopital Nord

    Saint-Etienne, France

  • Hopitaux Universitaires de Strasbourg - Le Nouvel Hopital Civil (NHC)

    Strasbourg, France

  • Hôpital Sainte Musse

    Toulon, France

  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital de Rangueil - Service de medecine vasculaire

    Toulouse, France

  • UNIVERSITAETSKLINIKUM FREIBURG - Universitaets-Herzzentrum Bad Krozingen | Klinik für Kardiologie und Angiologie

    Bad Krozingen, Germany

  • Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden | Medizinische Klinik I - FB Haemostaseologie

    Dresden, Germany

  • LMU Klinikum Campus Innenstadt | Medizinische Klinik und Poliklinik IV | FB Angiologie

    München, Germany

  • Universitaetsklinikum Muenster | Klinik fuer Kardiologie I Sektion Angiologie

    Münster, Germany

  • General Hospital Of Athens G Gennimatas- Department of Vascular Surgery

    Athens, Greece

  • University General Hospital Attikon - 1st Department of Vascular surgery University of Athens

    Athens, Greece

  • General Hospital Of Thessaloniki Papageorgiou- 1st Department of Surgery

    Efkarpia, Greece

  • University General Hospital Of Ioannina- Department of Surgery, Vascular Unit Faculty

    Ioannina, Greece

  • General University Hospital Of Patras- Department of Vascular Surgery

    Pátrai, Greece

  • Bekes Varmegyei Kozponti Korhaz - Dr. Rethy Pal Tagkorhaz

    Békéscsaba, Hungary

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.